Centers for Disease Control and Prevention
CDC 24/7: Saving Lives. Protecting People.™

Archived Editions (COVID-19 Genomics and Precision Public Health Weekly Update)

Published on 05/27/2021

COVID-19 Genomics and Precision Public Health Weekly Update Content

- Pathogen and Human Genomics Studies
- Non-Genomics Precision Health Studies
- News, Reviews and Commentaries

Pathogen and Human Genomics Studies

- Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1221)
  M Yuan et al, Science, May 20, 2021

  Neutralizing antibodies (nAbs) elicited against the receptor-binding site (RBS) of the spike protein of wild-type SARS-CoV-2 are generally less effective against recent variants of concern. RBS residues E484, K417 and N501 are mutated in variants first described in South Africa (B.1.351) and Brazil (P.1). We analyzed their effects on ACE2 binding and K417N and E484K mutations on nAbs isolated from COVID-19 patients. Binding and neutralization of the two most frequently elicited antibody families (IGHV3-53/3-66 and IGHV1-2), which can both bind the RBS in alternate binding modes, are abrogated by K417N, E484K, or both.

- Epidemiology and genetic diversity of SARS-CoV-2 lineages circulating in Africa (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1223)
  OS Okoh et al, MEDRXIV, May 19, 2021

  We show that after almost one year of the COVID-19 pandemic, only 143 out of the 782 Pango lineages found worldwide circulated in Africa, with five different lineages dominating in distinct periods of the pandemic. Analysis of the number of reported deaths in Africa also revealed large heterogeneity across the continent. Phylogenetic analysis revealed that African viruses cluster closely with those from all continents but more notably with viruses from Europe. However, the extent of viral diversity observed among African genomes is closest to that of the Oceania outbreak, most likely due to genomic under-surveillance in Africa.

- ACE2 and SARS-CoV-2 Infection Risk: Insights From Patients With Two Rare Genetic Tubulopathies, Gitelman's and Bartter's Syndromes. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1229)

Calò Lorenzo A et al. Frontiers in medicine 2021 5 647319

- SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1233)
  Ramanathan Muthukumar et al. The Lancet. Infectious diseases 2021 5
- Identification and trajectory of growth of concerning SARS-CoV-2 variants in Houston, Texas, January through April 2021 based on 11,568 genome sequences (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1238)
  RJ Olsen et al, MEDRXIV, May 23, 2021

  > The SARS-CoV-2 variant designated UK B.1.1.7 increased very rapidly, and now causes 75%-90% of all new cases in the Houston area. Five of the 2,543 B.1.1.7 genomes had an E484K change in spike protein. Compared with non-B.1.1.7 patients, individuals infected with B.1.1.7 had a significantly lower cycle threshold value (considered to be a proxy for higher virus load) and higher rate of hospitalization. Other variants (e.g., B.1.429, B.1.427, P.1, P.2, and R.1) also increased rapidly in frequency, although the magnitude was less than for B.1.1.7.

- Effectiveness of COVID-19 vaccines against the B.1.617.2 variant (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1241)
  JL Bernard et al, MEDRXIV, May 24, 2021

  > After 2 doses of either vaccine there were only modest differences in vaccine effectiveness with the B.1.617.2 variant. Absolute differences in vaccine effectiveness were more marked with dose 1. This would support maximising vaccine uptake with two doses among vulnerable groups.

- Emergence of SARS-CoV-2 variants of concern in the pediatric population of the United States (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1242)
  JD Bard et al, MEDRXIV, May 24, 2021

  > We report data from a genomic surveillance program that includes 9 U.S. children's hospitals. Analysis of SARS-CoV-2 genome from 2119 patients <19 years old between 03/20 to 04/21 identified 252 VOCs and 560 VOC signature mutations, most from 10/20 onwards. From 02/21 to 04/21, B.1.1.7 prevalence increased from 3.85% to 72.22% corresponding with the decline of B.1.429/B.1.427 from 51.82% to 16.67% at one institution. 71.74% of the VOC signature mutations detected were in children <12 years old, including 33 cases of B.1.1.7 and 119 of B.1.429/B.1.427.

- COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1248)
  FJ Naveca et al, Nature Medicine, May 25, 2021

  > Through a genomic epidemiology study based on 250?severe acute respiratory syndrome coronavirus?2 (SARS-CoV-2) genomes from different Amazonas municipalities sampled between March 2020 and January 2021, we reveal that the first exponential growth phase was driven mostly by the dissemination of lineage B.1.195, which was gradually replaced by lineage B.1.1.28 between May and June 2020. The second wave coincides with the emergence of the variant of concern (VOC) P.1, which evolved from a local B.1.1.28 clade in late November 2020 and replaced the parental lineage in <2?months.

- Variants of concern are overrepresented among post-vaccination breakthrough infections of SARS-

CoV-2 in Washington State (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1249)
AE McEwen et al, MEDRXIV, May 25, 2021

> Across 20 vaccine breakthrough cases detected at our institution, all 20 (100%) infections were due to variants of concern (VOC) and had a median Ct of 20.2 (IQR=17.1-23.3). When compared to 5174 contemporaneous samples sequenced in our laboratory, VOC were significantly enriched among breakthrough infections (p < .05).

Non-Genomics Precision Health Studies

- Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1221)
  M Yuan et al, Science, May 20, 2021

  > Neutralizing antibodies (nAbs) elicited against the receptor-binding site (RBS) of the spike protein of wild-type SARS-CoV-2 are generally less effective against recent variants of concern. RBS residues E484, K417 and N501 are mutated in variants first described in South Africa (B.1.351) and Brazil (P.1). We analyzed their effects on ACE2 binding and K417N and E484K mutations on nAbs isolated from COVID-19 patients. Binding and neutralization of the two most frequently elicited antibody families (IGHV3-53/3-66 and IGHV1-2), which can both bind the RBS in alternate binding modes, are abrogated by K417N, E484K, or both.

- Epidemiology and genetic diversity of SARS-CoV-2 lineages circulating in Africa (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1223)
  OS Okoh et al, MEDRXIV, May 19, 2021

  > We show that after almost one year of the COVID-19 pandemic, only 143 out of the 782 Pango lineages found worldwide circulated in Africa, with five different lineages dominating in distinct periods of the pandemic. Analysis of the number of reported deaths in Africa also revealed large heterogeneity across the continent. Phylogenetic analysis revealed that African viruses cluster closely with those from all continents but more notably with viruses from Europe. However, the extent of viral diversity observed among African genomes is closest to that of the Oceania outbreak, most likely due to genomic under-surveillance in Africa.

- ACE2 and SARS-CoV-2 Infection Risk: Insights From Patients With Two Rare Genetic Tubulopathies, Gitelman's and Bartter's Syndromes. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1229)
  Calò Lorenzo A et al. Frontiers in medicine 2021 5 647319

- SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1233)
  Ramanathan Muthukumar et al. The Lancet. Infectious diseases 2021 5

- Identification and trajectory of growth of concerning SARS-CoV-2 variants in Houston, Texas, January through April 2021 based on 11,568 genome sequences (/PHGKB/phgHome.action?

action=forward&dbsource=covUpdate&id=1238)
RJ Olsen et al, MEDRXIV, May 23, 2021

> The SARS-CoV-2 variant designated UK B.1.1.7 increased very rapidly, and now causes 75%-90% of all new cases in the Houston area. Five of the 2,543 B.1.1.7 genomes had an E484K change in spike protein. Compared with non-B.1.1.7 patients, individuals infected with B.1.1.7 had a significantly lower cycle threshold value (considered to be a proxy for higher virus load) and higher rate of hospitalization. Other variants (e.g., B.1.429, B.1.427, P.1, P.2, and R.1) also increased rapidly in frequency, although the magnitude was less than for B.1.1.7.

- Effectiveness of COVID-19 vaccines against the B.1.617.2 variant (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1241)
  JL Bernard et al, MEDRXIV, May 24, 2021

> After 2 doses of either vaccine there were only modest differences in vaccine effectiveness with the B.1.617.2 variant. Absolute differences in vaccine effectiveness were more marked with dose 1. This would support maximising vaccine uptake with two doses among vulnerable groups.

- Emergence of SARS-CoV-2 variants of concern in the pediatric population of the United States (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1242)
  JD Bard et al, MEDRXIV, May 24, 2021

> We report data from a genomic surveillance program that includes 9 U.S. children's hospitals. Analysis of SARS-CoV-2 genome from 2119 patients <19 years old between 03/20 to 04/21 identified 252 VOCs and 560 VOC signature mutations, most from 10/20 onwards. From 02/21 to 04/21, B.1.1.7 prevalence increased from 3.85% to 72.22% corresponding with the decline of B.1.429/B.1.427 from 51.82% to 16.67% at one institution. 71.74% of the VOC signature mutations detected were in children <12 years old, including 33 cases of B.1.1.7 and 119 of B.1.429/B.1.427.

- COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1248)
  FJ Naveca et al, Nature Medicine, May 25, 2021

> Through a genomic epidemiology study based on 250?severe acute respiratory syndrome coronavirus?2 (SARS-CoV-2) genomes from different Amazonas municipalities sampled between March 2020 and January 2021, we reveal that the first exponential growth phase was driven mostly by the dissemination of lineage B.1.195, which was gradually replaced by lineage B.1.1.28 between May and June 2020. The second wave coincides with the emergence of the variant of concern (VOC) P.1, which evolved from a local B.1.1.28 clade in late November 2020 and replaced the parental lineage in <2?months.

- Variants of concern are overrepresented among post-vaccination breakthrough infections of SARS-CoV-2 in Washington State (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1249)
  AE McEwen et al, MEDRXIV, May 25, 2021

> Across 20 vaccine breakthrough cases detected at our institution, all 20 (100%) infections were due to variants of concern (VOC) and had a median Ct of 20.2 (IQR=17.1-23.3). When compared to 5174 contemporaneous samples sequenced in our laboratory, VOC were significantly enriched

among breakthrough infections (p < .05).

News, Reviews and Commentaries

- Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1221)
  M Yuan et al, Science, May 20, 2021

  Neutralizing antibodies (nAbs) elicited against the receptor-binding site (RBS) of the spike protein of wild-type SARS-CoV-2 are generally less effective against recent variants of concern. RBS residues E484, K417 and N501 are mutated in variants first described in South Africa (B.1.351) and Brazil (P.1). We analyzed their effects on ACE2 binding and K417N and E484K mutations on nAbs isolated from COVID-19 patients. Binding and neutralization of the two most frequently elicited antibody families (IGHV3-53/3-66 and IGHV1-2), which can both bind the RBS in alternate binding modes, are abrogated by K417N, E484K, or both.
- Epidemiology and genetic diversity of SARS-CoV-2 lineages circulating in Africa (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1223)
  OS Okoh et al, MEDRXIV, May 19, 2021

  We show that after almost one year of the COVID-19 pandemic, only 143 out of the 782 Pango lineages found worldwide circulated in Africa, with five different lineages dominating in distinct periods of the pandemic. Analysis of the number of reported deaths in Africa also revealed large heterogeneity across the continent. Phylogenetic analysis revealed that African viruses cluster closely with those from all continents but more notably with viruses from Europe. However, the extent of viral diversity observed among African genomes is closest to that of the Oceania outbreak, most likely due to genomic under-surveillance in Africa.
- ACE2 and SARS-CoV-2 Infection Risk: Insights From Patients With Two Rare Genetic Tubulopathies, Gitelman's and Bartter's Syndromes. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1229)
  Calò Lorenzo A et al. Frontiers in medicine 2021 5 647319
- SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity. (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1233)
  Ramanathan Muthukumar et al. The Lancet. Infectious diseases 2021 5
- Identification and trajectory of growth of concerning SARS-CoV-2 variants in Houston, Texas, January through April 2021 based on 11,568 genome sequences (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1238)
  RJ Olsen et al, MEDRXIV, May 23, 2021

  The SARS-CoV-2 variant designated UK B.1.1.7 increased very rapidly, and now causes 75%-90% of all new cases in the Houston area. Five of the 2,543 B.1.1.7 genomes had an E484K change in spike protein. Compared with non-B.1.1.7 patients, individuals infected with B.1.1.7 had a significantly lower cycle threshold value (considered to be a proxy for higher virus load) and higher rate of hospitalization. Other variants (e.g., B.1.429, B.1.427, P.1, P.2, and R.1) also increased rapidly in frequency, although the magnitude was less than for B.1.1.7.

- Effectiveness of COVID-19 vaccines against the B.1.617.2 variant (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1241)
  JL Bernard et al, MEDRXIV, May 24, 2021

  After 2 doses of either vaccine there were only modest differences in vaccine effectiveness with the B.1.617.2 variant. Absolute differences in vaccine effectiveness were more marked with dose 1. This would support maximising vaccine uptake with two doses among vulnerable groups.

- Emergence of SARS-CoV-2 variants of concern in the pediatric population of the United States (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1242)
  JD Bard et al, MEDRXIV, May 24, 2021

  We report data from a genomic surveillance program that includes 9 U.S. children's hospitals. Analysis of SARS-CoV-2 genome from 2119 patients <19 years old between 03/20 to 04/21 identified 252 VOCs and 560 VOC signature mutations, most from 10/20 onwards. From 02/21 to 04/21, B.1.1.7 prevalence increased from 3.85% to 72.22% corresponding with the decline of B.1.429/B.1.427 from 51.82% to 16.67% at one institution. 71.74% of the VOC signature mutations detected were in children <12 years old, including 33 cases of B.1.1.7 and 119 of B.1.429/B.1.427.

- COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1248)
  FJ Naveca et al, Nature Medicine, May 25, 2021

  Through a genomic epidemiology study based on 250?severe acute respiratory syndrome coronavirus?2 (SARS-CoV-2) genomes from different Amazonas municipalities sampled between March 2020 and January 2021, we reveal that the first exponential growth phase was driven mostly by the dissemination of lineage B.1.195, which was gradually replaced by lineage B.1.1.28 between May and June 2020. The second wave coincides with the emergence of the variant of concern (VOC) P.1, which evolved from a local B.1.1.28 clade in late November 2020 and replaced the parental lineage in <2?months.

- Variants of concern are overrepresented among post-vaccination breakthrough infections of SARS-CoV-2 in Washington State (/PHGKB/phgHome.action?action=forward&dbsource=covUpdate&id=1249)
  AE McEwen et al, MEDRXIV, May 25, 2021

  Across 20 vaccine breakthrough cases detected at our institution, all 20 (100%) infections were due to variants of concern (VOC) and had a median Ct of 20.2 (IQR=17.1-23.3). When compared to 5174 contemporaneous samples sequenced in our laboratory, VOC were significantly enriched among breakthrough infections ($p < .05$).

Disclaimer*: Articles listed in COVID-19 Genomics and Precision Public Health Weekly Update are selected by the CDC Office of Public Health Genomics to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items*

Page last reviewed: Oct 1, 2020

Page last updated: May 30, 2021

Content source: Office of Genomics and Precision Public Health (http://www.cdc.gov/genomics/), CDC Office of Science (https://www.cdc.gov/od/science/index.htm)